MedTrace Logo

Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome

NCT01080872 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2011-05-05

No results posted yet for this study

Summary

The aim of the trial is to assess coronary artery reactivity using adenosine-induced coronary flow reserve (CFR) by transthoracic echocardiography in patients with Bio-active stent (BAS) and Everolimus-eluting stent (EES) distal to the original culprit lesion at 6-8 months.

Conditions

  • Acute Coronary Syndrome

Interventions

DEVICE

CFR

CFR will be assessed using transthoracic echocardiography with adenosine infusion.

Sponsors & Collaborators

  • The Hospital District of Satakunta

    lead OTHER

Principal Investigators

  • Tuomas O Kiviniemi, MD PhD · Satakunta Central Hospital

  • Antti Saraste, MD PhD · Turku University Hospital

  • Pasi P Karjalainen, MD PhD · Satakunta Central Hospital

  • Antti Ylitalo, MD PhD · Satakunta Central Hospital

  • Jussi Mikkelsson, MD PhD · Satakunta Central Hospital

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01080872 on ClinicalTrials.gov